On January 31, 2018 Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA) constructs, reported that Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company update at the annual BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 1:45 pm EST at the New York Marriott Marquis in New York City (Press release, Exicure, JAN 31, 2018, View Source;p=RssLanding&cat=news&id=2329459 [SID1234523655]). The company will also present at the Immuno-Oncology 360° Summit (IO360°) on Thursday, February 8, 2018 at 11:15 am EST. This meeting will take place at The Roosevelt Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, the company plans to present a company overview at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 9:30 am EST at the Lotte New York Palace Hotel in New York City.

A live webcast of the BIO CEO & Investor Conference and the LEERINK Partners Global Healthcare Conference presentations will be available on the Events & Presentations section of Exicure’s website and will also be archived.